Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04908202 · ClinicalTrials.gov registry record · Phase 3

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Phase 3 study of Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
670
Enrollment target
20
Study locations

NCT04908202 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 670 participants, below the 839-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04908202, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
670 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Conditions Studied

Psoriatic Arthritis

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib

Study Locations (20)

California

  • Local Institution - 0168 - Fontana
  • Local Institution - 0199 - Fullerton
  • Local Institution - 0038 - Sacramento
  • Cohen Medical Centers - Thousand Oaks

Florida

  • Local Institution - 0195 - Clearwater
  • Local Institution - 0272 - Margate
  • Local Institution - 0082 - Miami Lakes

Illinois

  • Local Institution - 0080 - Chicago
  • Local Institution - 0177 - Orland Park
  • Local Institution - 0178 - Schaumburg

Arizona

  • Local Institution - 0197 - Gilbert

Arkansas

  • Local Institution - 0188 - Jonesboro

Colorado

  • Local Institution - 0170 - Denver

Georgia

  • Local Institution - 0171 - Gainesville

Idaho

  • Local Institution - 0087 - Boise

Trial Details

FieldValue
Enrollment Target 670 participants
Start Date 2021-07-13
Est. Completion 2027-06-10
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04908202

The ClinicalTrials.gov registry entry for NCT04908202 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 839-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (20% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04908202 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT04908202 about?

NCT04908202 is a clinical study titled "A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs". The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety in...

What is the current status of trial NCT04908202?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2021-07-13. Estimated completion is 2027-06-10.

What conditions does trial NCT04908202 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT04908202?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT04908202?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04908202 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriatic Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.